Pepcid AC
This article was originally published in The Tan Sheet
Executive Summary
Launch of generic versions of market-leading OTC H2 antagonist apparently delayed due to patent dispute, FDA says. J&J/Merck's famotidine 10 mg had received six months of pediatric exclusivity, which expired April 15